Pub Date : 2023-12-01DOI: 10.1007/s44164-023-00063-y
Mehran Radak, Hossein Fallahi
{"title":"Identification and prediction of molecular factors associated with ischemic stroke: an integrative analysis of DEGs, TFs, and PPI networks","authors":"Mehran Radak, Hossein Fallahi","doi":"10.1007/s44164-023-00063-y","DOIUrl":"https://doi.org/10.1007/s44164-023-00063-y","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":" 19","pages":"307 - 315"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138612831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-13DOI: 10.1007/s44164-023-00061-0
K. C. Ashitha, Gopinath M, Sasirekha N.R, Balakumar S, Rajashree P
Cancer represents a significant cause of morbidity and mortality. Definitive chemotherapy, surgery and radiotherapy treatment have not improved the “5-year survival period” and have shown recurrence. Currently, cancer immunotherapy is reported to be a promising therapeutic modality that aims to potentiate immune response against cancer by employing immune checkpoint inhibitors, cancer vaccines and immunomodulators. Inhibition of immune checkpoints such as PD-1/PDL1, CTLA and TIM molecules using monoclonal antibodies, ligands or both are proven to be the most successful anticancer immunotherapy. But the application of immunotherapy involves critical challenges such as non-responsiveness and systemic toxicity due to the administration of high dose. To mitigate the above challenges, nanomaterial-based delivery and therapy have been adopted to inhibit the immune checkpoints and induce an anticancer immune response. Specifically, mesoporous silica-based materials for cancer therapy are shown to be versatile materials for the above purpose. Mesoporous silica nanoparticle (MSN) based cancer immunotherapy overcomes numerous challenges and offers novel strategies for improving conventional immunotherapies. MSN has a high surface area, porosity and biocompatibility; it also has natural immune-adjuvant properties, which have been reported to be the best candidate material for immunotherapeutic delivery. This review will focus on the use of MSN as carriers for delivering immune checkpoint inhibitors and their efficacy in cancer combination therapy.
{"title":"Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer","authors":"K. C. Ashitha, Gopinath M, Sasirekha N.R, Balakumar S, Rajashree P","doi":"10.1007/s44164-023-00061-0","DOIUrl":"https://doi.org/10.1007/s44164-023-00061-0","url":null,"abstract":"Cancer represents a significant cause of morbidity and mortality. Definitive chemotherapy, surgery and radiotherapy treatment have not improved the “5-year survival period” and have shown recurrence. Currently, cancer immunotherapy is reported to be a promising therapeutic modality that aims to potentiate immune response against cancer by employing immune checkpoint inhibitors, cancer vaccines and immunomodulators. Inhibition of immune checkpoints such as PD-1/PDL1, CTLA and TIM molecules using monoclonal antibodies, ligands or both are proven to be the most successful anticancer immunotherapy. But the application of immunotherapy involves critical challenges such as non-responsiveness and systemic toxicity due to the administration of high dose. To mitigate the above challenges, nanomaterial-based delivery and therapy have been adopted to inhibit the immune checkpoints and induce an anticancer immune response. Specifically, mesoporous silica-based materials for cancer therapy are shown to be versatile materials for the above purpose. Mesoporous silica nanoparticle (MSN) based cancer immunotherapy overcomes numerous challenges and offers novel strategies for improving conventional immunotherapies. MSN has a high surface area, porosity and biocompatibility; it also has natural immune-adjuvant properties, which have been reported to be the best candidate material for immunotherapeutic delivery. This review will focus on the use of MSN as carriers for delivering immune checkpoint inhibitors and their efficacy in cancer combination therapy.","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"61 43","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136283763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-07DOI: 10.1007/s44164-023-00062-z
Subramaina Balakumar, Vijayakumari Sugumaran
{"title":"Special issue: recent trends in bionanomaterials for health care applications","authors":"Subramaina Balakumar, Vijayakumari Sugumaran","doi":"10.1007/s44164-023-00062-z","DOIUrl":"https://doi.org/10.1007/s44164-023-00062-z","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"14 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135480576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-27DOI: 10.1007/s44164-023-00060-1
J. Miguel Oliveira
{"title":"Complex in vitro models: do not complicate it","authors":"J. Miguel Oliveira","doi":"10.1007/s44164-023-00060-1","DOIUrl":"https://doi.org/10.1007/s44164-023-00060-1","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135535312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.1007/s44164-023-00058-9
V. L. Workman, A-V. Giblin, N. H. Green, S. MacNeil, V. Hearnden
Abstract Tissue-engineered models of skin have evolved over the past 50 years, have successfully been translated to clinical use and continue to be improved using new technologies. However, very few of these constructs incorporate a hypodermal component. The hypodermis is critical to skin homeostasis, skin function and many skin diseases, but our understanding of the hypodermis is limited in comparison to our knowledge of the epidermis and dermis, in part due to a lack of suitable in vitro models. The purpose of this study was to develop and characterise a tissue-engineered model of skin consisting of epidermal, dermal and hypodermal layers, namely a trilayer skin model. Models were produced by culturing human keratinocytes and fibroblasts on decellularised human dermis in combination with explanted human adipose tissue. Bilayer models of skin, comprising of an epidermis and dermis, had a thicker epidermal component compared to trilayer models but exhibited similar cytokeratin expression patterns (AE1/AE3 and cytokeratin 14). Addition of adipose tissue improved the appearance of the dermal-epidermal junction, increased the number of rete ridge-like features and cells maintained similar levels of proliferation (Ki-67) compared to native tissues over 28 days in culture. This technique enabled us to create a physiologically relevant model of human skin with representative morphology across the hypodermis, dermis and epidermis. This model maintained native extracellular matrix architecture, contained a heterogeneous population of cells and has the potential to be applied to a range of different applications where research questions require the inclusion of a hypodermis.
{"title":"Development of a tissue-engineered skin model with epidermal, dermal and hypodermal components","authors":"V. L. Workman, A-V. Giblin, N. H. Green, S. MacNeil, V. Hearnden","doi":"10.1007/s44164-023-00058-9","DOIUrl":"https://doi.org/10.1007/s44164-023-00058-9","url":null,"abstract":"Abstract Tissue-engineered models of skin have evolved over the past 50 years, have successfully been translated to clinical use and continue to be improved using new technologies. However, very few of these constructs incorporate a hypodermal component. The hypodermis is critical to skin homeostasis, skin function and many skin diseases, but our understanding of the hypodermis is limited in comparison to our knowledge of the epidermis and dermis, in part due to a lack of suitable in vitro models. The purpose of this study was to develop and characterise a tissue-engineered model of skin consisting of epidermal, dermal and hypodermal layers, namely a trilayer skin model. Models were produced by culturing human keratinocytes and fibroblasts on decellularised human dermis in combination with explanted human adipose tissue. Bilayer models of skin, comprising of an epidermis and dermis, had a thicker epidermal component compared to trilayer models but exhibited similar cytokeratin expression patterns (AE1/AE3 and cytokeratin 14). Addition of adipose tissue improved the appearance of the dermal-epidermal junction, increased the number of rete ridge-like features and cells maintained similar levels of proliferation (Ki-67) compared to native tissues over 28 days in culture. This technique enabled us to create a physiologically relevant model of human skin with representative morphology across the hypodermis, dermis and epidermis. This model maintained native extracellular matrix architecture, contained a heterogeneous population of cells and has the potential to be applied to a range of different applications where research questions require the inclusion of a hypodermis.","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136154104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tumor spheroids are one of the well-characterized 3D culture systems bearing close resemblance to the physiological tissue organization and complexity of avascular solid tumor stage with hypoxic core. They hold a wide-spread application in the field of pharmaceutical science and anti-cancer drug research. However, the difficulty in determining optimal technique for the generation of spheroids with uniform size and shape, evaluation of experimental outputs, or mass production often limits their usage in anti-cancer research and in high-throughput drug screening. In recent times, several studies have demonstrated various simple techniques for generating uniform-size 3D spheroids, including the hanging drop (HD), liquid overlay technique (LOT), and microfluidic approaches. Morphological alterations apart from biochemical assays, and staining techniques are suitably employed for the evaluation of experimental outcomes within 3D spheroid models. Morphological alterations in response to effective anti-cancer drug treatment in 3D tumor spheroids such as reduced spheroid size, loss of spheroid compactness and integrity or smooth surface, are highly reliable. These alterations can significantly reduce the need for biochemical assays and staining techniques, resulting in both time and cost savings. The present article specifically covers a variety of available procedures in spheroid generation. For practical applicability, we have supplemented our review study with the generation of glioblastoma U87 spheroids using HD and LOT methods. Additionally, we have also incorporated the outcome of U87 spheroid treatment with doxorubicin on spheroid morphology.
{"title":"3D tumor spheroids: morphological alterations a yardstick to anti-cancer drug response","authors":"Anna Senrung, Sakshi Lalwani, Divya Janjua, Tanya Tripathi, Jasleen Kaur, Netra Ghuratia, Nikita Aggarwal, Arun Chhokar, Joni Yadav, Apoorva Chaudhary, Udit Joshi, Alok Chandra Bharti","doi":"10.1007/s44164-023-00059-8","DOIUrl":"https://doi.org/10.1007/s44164-023-00059-8","url":null,"abstract":"Tumor spheroids are one of the well-characterized 3D culture systems bearing close resemblance to the physiological tissue organization and complexity of avascular solid tumor stage with hypoxic core. They hold a wide-spread application in the field of pharmaceutical science and anti-cancer drug research. However, the difficulty in determining optimal technique for the generation of spheroids with uniform size and shape, evaluation of experimental outputs, or mass production often limits their usage in anti-cancer research and in high-throughput drug screening. In recent times, several studies have demonstrated various simple techniques for generating uniform-size 3D spheroids, including the hanging drop (HD), liquid overlay technique (LOT), and microfluidic approaches. Morphological alterations apart from biochemical assays, and staining techniques are suitably employed for the evaluation of experimental outcomes within 3D spheroid models. Morphological alterations in response to effective anti-cancer drug treatment in 3D tumor spheroids such as reduced spheroid size, loss of spheroid compactness and integrity or smooth surface, are highly reliable. These alterations can significantly reduce the need for biochemical assays and staining techniques, resulting in both time and cost savings. The present article specifically covers a variety of available procedures in spheroid generation. For practical applicability, we have supplemented our review study with the generation of glioblastoma U87 spheroids using HD and LOT methods. Additionally, we have also incorporated the outcome of U87 spheroid treatment with doxorubicin on spheroid morphology.","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"89 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136375228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-21DOI: 10.1007/s44164-023-00056-x
M. Müller, R. Drexel, Marie Burkhart, S. Dähnhardt-Pfeiffer, Lena Wien, C. Herrmann, Thorsten Knoll, C. Metzger, H. Briesen, Sylvia Wagner, F. Meier, Y. Kohl
{"title":"Ex vivo models for intestinal translocation studies of cellulose nanocrystals","authors":"M. Müller, R. Drexel, Marie Burkhart, S. Dähnhardt-Pfeiffer, Lena Wien, C. Herrmann, Thorsten Knoll, C. Metzger, H. Briesen, Sylvia Wagner, F. Meier, Y. Kohl","doi":"10.1007/s44164-023-00056-x","DOIUrl":"https://doi.org/10.1007/s44164-023-00056-x","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84388291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-15DOI: 10.1007/s44164-023-00057-w
S. Cherradi, Nicolas Taulet, Hong T Duong
{"title":"An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk","authors":"S. Cherradi, Nicolas Taulet, Hong T Duong","doi":"10.1007/s44164-023-00057-w","DOIUrl":"https://doi.org/10.1007/s44164-023-00057-w","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85172174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-02DOI: 10.1007/s44164-023-00055-y
Marie-Juliet Brown, Matt Nickels, E. Akam, Mhairi A. Morris
{"title":"The protective effect of endurance running against the pro-invasive effects of ageing in breast cancer cells and mesenchymal stem cells in vitro","authors":"Marie-Juliet Brown, Matt Nickels, E. Akam, Mhairi A. Morris","doi":"10.1007/s44164-023-00055-y","DOIUrl":"https://doi.org/10.1007/s44164-023-00055-y","url":null,"abstract":"","PeriodicalId":73357,"journal":{"name":"In vitro models","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87519743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：